ORKA is up 12.70% today. Volume is 1.94M vs a 30-day average of 994.2K (1.95x).
Oruka Therapeutics, Inc. is scheduled to report earnings Wed, Nov 18, 2026. Analysts expect EPS of $-0.62. Stocks often move sharply on earnings day.
Key TakeawaysOruka Therapeutics shares rose 12% after ORKA-001, its drug for psoriasis, completely cleared the skin of 61% of patients on the high dose at Week 16 of its Phase 2b …
Oruka said about 61% of patients receiving the highest 600 mg dose achieved PASI 100 after week 16, compared with none receiving placebo.
2026-10-26. The following slide deck was published by Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis October 26, 2026 8:00 AM EDTCompany ParticipantsAlan...
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p1…